Astex

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Research, Technology, Neurology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, IND, Type 2, Hart–Scott–Rodino Antitrust Improvements Act, Publication, Therapy, CNS, TYK2, LRRK2, Strategic planning, FDA, Pancreatic serous cystadenoma, Psoriasis, Neurology, Astex, MALT1, Ulcerative colitis, ASH, Manuscript, CDC7, Drug discovery, Takeda, Patient, Drug design, Webcast, Software, Ajax, MBBS, Blog, Society, UC, Bristol Myers Squibb, Annual general meeting, Ōtsuka, Pharmaceutical industry, Nimbus

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.
  • Schrödinger reported a new program targeting LRRK2, a genetically validated target with therapeutic potential for the treatment of Parkinson’s disease.
  • In 2022, Schrödinger generated cryo-electron microscopy structures of LRRK2 which is helping to accelerate the identification of novel LRRK2 inhibitors.
  • Today Schrödinger outlined the following strategic priorities for 2023:
    Schrödinger will report its fourth quarter and full-year financial results and provide 2023 financial guidance on Tuesday, February 28, 2023, after the financial markets close.

Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours

Retrieved on: 
Saturday, December 31, 2022
Ecosystem, OBE, Central nervous system, Drug discovery, Science, Growth, Patient, FRS, Ōtsuka, Harren Jhoti, Doctor of Philosophy, Pharmaceutical industry, Fellow of the Academy of Medical Sciences, Astex

CAMBRIDGE, United Kingdom, Dec. 31, 2022 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list.

Key Points: 
  • CAMBRIDGE, United Kingdom, Dec. 31, 2022 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list.
  • Dr. Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.
  • Prof. Sir Tom Blundell FRS, an Astex co-founder and Board member, commented, ‘‘This honour is very well deserved.
  • It underlines Harren’s qualities as an innovator, entrepreneur and leader at Astex.

Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Pneumonia, Intracranial hemorrhage, Society, Research, Toxicity, Anemia, Aplastic anemia, Child, Acute kidney injury, Ōtsuka, NCCN, Woman, Patient, Sepsis, MDS, Bone marrow suppression, Risk, CMML, Thrombocytopenia, Fatal, Microdeletion syndrome, MLF, International Prognostic Index, AUC, MOS, Birth, Febrile neutropenia, Clinical trial, National Comprehensive Cancer Network, Abstract, Neutropenia, Creatinine, ESRD, Pregnancy, De novo, Decitabine, Chronic kidney disease, TP53, Confidence interval, ASH, Mutation, Chronic myelomonocytic leukemia, Route of administration, Internal medicine, Sudden death, LFS, Kidney, Septic shock, Myelodysplastic syndrome, Vanderbilt University, Astex, Chromosomal deletion syndrome, IV, Fetus, Pharmaceutical industry, Birth control, Epidemiology, MD

PRINCETON, N.J. and PLEASANTON, Calif., Dec. 12, 2022 /PRNewswire/ -- Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced preliminary data from the Phase 3 ASCERTAIN trial assessing overall and leukemia-free survival in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML) harboring biallelic TP53 mutations following treatment with oral decitabine and cedazuridine (ASTX727). The data are being presented today as an oral presentation (Abstract #854) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The data are being presented today as an oral presentation ( Abstract #854 ) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.
  • In the study, the population of patients harboring a TP53 mutation (44 of 125 patients) was characterized by allelic status: 14 patients had biallelic mutations and 30 patients had monoallelic mutations without other chromosomal deletions.
  • The primary endpoint of the study was total 5-day area-under-the-curve (AUC) equivalence of oral decitabine and cedazuridine and IV decitabine.
  • Astex, the Astex logo, Taiho Oncology, the Taiho Oncology logo and INQOVI are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries.

Inhibitor of Apoptosis (IAP) Antagonist Drug Pipeline Market Insights Report 2022 Featuring Merck & Co., Novartis, Astex Pharmaceuticals, Ascentage Pharma, & Chia Tai Tianqing Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, General Health, IAP, Antagonist, Clinical trial, Neoplasm, Cell death, III, Route, News, T-cell lymphoma, Route of administration, IAPS, Merck & Co., Discovery, II, NDA, XIAP, Acquisition, Inhibitor of apoptosis, Administration, Therapy, Astex, CRT, Head, Patient, Pharmaceutical industry, Vaccine, Merck, Apoptosis

This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.

Key Points: 
  • This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.
  • The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Inhibitor of Apoptosis (IAP) Antagonist drug candidates in the most advanced stage, i.e.
  • phase III include, Merck & Co.
    Inhibitor of Apoptosis (IAP) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

Retrieved on: 
Tuesday, November 22, 2022
Patient, Novartis, Clinical trial, Biomedical Research, Physician, NIBR, Novartis Institute for Tropical Diseases, Astex, Research, Marketing, Sale, Government, Regulation, Safety, Pharmaceutical industry, COVID-19

Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.

Key Points: 
  • Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.
  • This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.
  • Located in East Hanover, NJ Novartis Pharmaceuticals Corporation an affiliate of Novartis is reimagining medicine to improve and extend people's lives.
  • * Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.

Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diamond, Lists of diseases, Master of Science, Drug design, Diamond Light Source, University of Nottingham, GSK, Therapy, Disease, Hope, Science, Amphisbaena, Nobel Prize, University, Max Planck Institute of Biochemistry, Drug development, Research, Joint Planning and Development Office, Villigen, Astex, Institute, Partnership, Olaparib, Artificial intelligence, Cancer, Gene, Max Planck Society, Probability, University College London, Drug discovery, Atlas, Doctor of Philosophy, Industry, Charles River Laboratories, Gesellschaft mit beschränkter Haftung, Cancer Research UK, Genetics, Genome, Head, GW Pharmaceuticals, Pharmaceutical industry, IND, Chemistry, Dodi Protero, Adrasteia

Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.

Key Points: 
  • Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.
  • He has led or been involved with the delivery of seven drug candidates across a range of target classes.
  • In Jamess most recent position he ran the medicinal chemistry function at Amphista Therapeutics.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new targets for treating intractable genetic diseases.

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Retrieved on: 
Thursday, September 15, 2022
Safety, Breast, Astex, Patient, Investment, Nasdaq, Silence Therapeutics, Communication, Time, COVID-19, Sirna, Intellectual property, CD34, MBA, Annual report, SAN, Tumor microenvironment, SEC, EMA, FDA, Review, Neoplasm, Exchange, CEO, AstraZeneca, Research and development, Board of directors, Board, Security (finance), GLOBE, Caladrius Biosciences, Cancer, Therapy, Development, CendR, Colorectal cancer, Prostate, Pancreatic cancer, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Risk, Lung, RNA, Management, Pharmaceutical industry, Research, Director, Mergers and acquisitions, Caladrius, Zeneca

BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. (“Lisata”) and will focus primarily on advancing its CendR Platform™ technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs. Lisata will commence trading on The Nasdaq Capital Market today, September 15, 2022, under the ticker symbol “LSTA”.

Key Points: 
  • Lisatas cash and investments, as of immediately following the closing of the merger, are approximately $76 million.
  • Prior to the closing of the merger, Caladrius effected a 1-for-15 reverse split of its common stock.
  • Pursuant to the merger agreement and upon the closing of the merger, three former Cend directors, including Erkki Ruoslahti, M.D., Ph.D., Heidi Henson, and David Slack, MBA, were appointed as directors.
  • Additionally, Lisata is pleased to announce that Mohammad Azab, M.D., M.Sc., MBA has been appointed to the Lisata Board of Directors.

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, Inflammation, University, Astex, Physician, Lymphatic system, Cancer, Research, Form 10-K, Carbohydrate, Food and Drug Administration, Hematology, GSK, AML, Macrogen, Risk, Food, Stanford University School of Medicine, SEC, Chemistry, Acute myeloid leukemia, Cell, U.S. Securities and Exchange Commission, Swarthmore College, Immunology, MD, Economics, Margetuximab, Nasdaq, FDA, Breakthrough therapy, Doctor of Philosophy, Company, Adult, E-selectin, Stanford University, Annual report, Bone marrow, Forward-looking statement, Patient, CMO, Pharmaceutical industry, Glycomimetic, Microbiology, Biology, Brigham

GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO).

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO).
  • We are thrilled to have Ed join the GlycoMimetics team.
  • He completed medical residency training at Brigham and Womens Hospital in Boston, MA, a medical oncology fellowship at the University of Pennsylvania, and a postdoctoral fellowship in vaccine engineering at Stanford.
  • Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, June 1, 2022
Oncology, Health, Surgery, General Health, Pharmaceutical, Biotechnology, Amgen, Genentech, Astex, CEO, Arcus, Stimulator of interferon genes, Research institute, Therapy, Patient, Stimulator, Technology, Tumor microenvironment, Cancer Prevention and Research Institute of Texas, Columbia University, Drug development, History, BioMarin Pharmaceutical, Cancer, Cancer prevention, Medical device, Medical imaging, Pharmaceutical industry

OncoNano Medicine, Inc. today announced the appointment of Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • OncoNano Medicine, Inc. today announced the appointment of Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer.
  • Dr. Krishnan will be responsible for formulating and leading all clinical development efforts and operations at OncoNano.
  • We are thrilled that OncoNano has been successful in attracting such a noted and impressive scientist as Dr. Krishnan.
  • Kartik is a proven and respected oncology drug developer, with extensive experience in leading the development of novel oncology therapeutic programs, said Martin Driscoll, CEO of OncoNano.

STipe Therapeutics appoints Dr Richard Sainson as Chief Scientific Officer to Lead Research and Discovery

Retrieved on: 
Tuesday, May 31, 2022
Senior, Immunotherapy, Pharmacology, F-star, VP, CSO, Stimulator of interferon genes, Doctor of Philosophy, Sanofi, Tumor microenvironment, Stipe, Therapy, University of California, Irvine academics, University, Research, Molecular biology, Astex, Industry, Biochemistry, Stimulator, Technology, Publication, Drug development, Pathway, CEO, Interferon, GLOBE, Pharmaceutical industry

He will be based in Aarhus, Denmark and report to Dr Claus Olesen, STipes Chief Executive Officer (CEO).

Key Points: 
  • He will be based in Aarhus, Denmark and report to Dr Claus Olesen, STipes Chief Executive Officer (CEO).
  • As CSO, Dr Sainson will lead the research and advancement of the Companys innovative science and platform technology.
  • I look forward to applying my experience and expertise to harness these strengths and to addressing the unmet needs of patients.
  • Richard Sainson has over 20 years of oncology research experience acquired both in academia and industry.